Piramal sells its CRO division to India's Indoco

Indian conglomerate Piramal has sold off its CRO business to Indoco Remedies, getting rid of a business "not considered strategic in nature," according to the company. Indoco is largely focused on drug manufacturing, and bringing in Piramal's 30,000-square-foot Hyderabad clinical research hub will get it onto India's CRO market. More